SCHEMBL16419754

SCHEMBL16419754

CCCCOc1cc(-c2ccc3ccc(-c4cc(OCCCN)c(OCCCN)c(OCCCN)c4)cc3c2)cc(OCCCN)c1OCCCN

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 2/20 0.40
▸ ACHE P22303 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ MCHR1 Q99705 1/20 0.37
▸ TLR8 Q9NR97 1/20 0.37
▸ CDC7 O00311 1/20 0.36
▸ ROCK2 O75116 1/20 0.36
▸ MAP4K4 O95819 1/20 0.36
▸ PIM1 P11309 1/20 0.36
▸ PRKACA P17612 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ HIPK2 Q9H2X6 1/20 0.36
▸ CLK4 Q9HAZ1 1/20 0.36
▸ IRAK4 Q9NWZ3 1/20 0.36
▸ HTR1B P28222 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16419784 0.93 HTR1B (0.40) SMN1; SMN2HTR1BCHRNB2CHRNB4CHRNA3
SCHEMBL16419743 0.82 CHRNB2 (0.43) SMN1; SMN2CYP1A2CYP2C9CYP2C19CHRNB2
SCHEMBL16169700 0.81 PIM1 (0.39) BCHEACHESMN1; SMN2GLACYP1A2
SCHEMBL16419762 0.81 CYP1A2 (0.45) BCHEACHESMN1; SMN2GLACYP1A2
SCHEMBL16169699 0.76 PIM1 (0.40) SMN1; SMN2GLACYP1A2CYP2C9CYP2C19
SCHEMBL16419778 0.74 CA12 (0.46) GLACYP2C19ALDH1A1KDM4EMAPT
SCHEMBL16419772 0.73 CSF3R (0.42) ROCK2MAP4K4PIM1PRKACACLK4
SCHEMBL15036875 0.72 HTR1B (0.45) SMN1; SMN2HTR1BMAPK1KDM4EHPGD
SCHEMBL9073465 0.70 ALDH1A1 (0.69) BCHEACHESMN1; SMN2GLACYP1A2
Hydrochloric Acid SCHEMBL9800188 0.68 ALDH1A1 (0.67) BCHEACHESMN1; SMN2GLACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469616-B2 Cyclic compounds and methods of making and using the same CELLCEUTIX CORPORATION (US) 2016-10-18 — — US disclosed
US-20150031738-A1 CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME UNIVERSITY OF MASSACHUSETTS (US) 2015-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031738-A1 CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MUC1, TLR3, ALG1 BCHE 3685/4885ACHE 2506/4885SMN1; SMN2 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback